Xbrane Biopharma AB (publ) (XBRANE) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

the webcast connected to the Q2 2025 report of Exprin Biopharma. My name is Martin Aumark. I'm the CEO and I have with me our CFO Jane also online. We will, as usually, go through the operational activities and an update for the quarter. I will start with that and then Jane will take over and go through the financials for the quarter. Then we will have a Q&A session afterwards in which you can, if you've called in, ask questions via audio or otherwise write questions in the chat. So let's start I'm shifting here to the first slide we will start to talk a little bit about Exim Lucy our Lucentis bisimilar then I will shift over and talk a little bit about Exdivane our Optivo bisimilar candidate as most of you that follow us knows we have one product which is being commercialized and that is Exim Lucy and by similar to Lucentis, an eye drug used in treatment of several severe eye diseases, mainly age-related macular degeneration. We have, since 2018, a co-development agreement with Stada, a German generics and biosimilar company with about 11,000 employees or so. we have co-developed the product and they are commercializing the product since March 2023 when we got an approval in Europe from EMA the arrangement is that we are essentially sharing the profit contribution from sales and marketing of the product 50 50 between the parties Ximulus is now launched by Stada in 24 countries out of which 20 in Europe and four in the Middle East and so we are gradually getting to cover the majority of the countries in Europe and we are also together with Stada expanding in the Middle East and broader Asia. and we'll go through a little bit where we're at we in looking at Europe only Ximilusi had a volume market share of eight percent in the quarter and that is looking at the Randev...